In the height of summer, as vitality flourishes across Beijing, the 8th GoBroad Medical Annual Meeting,  hosted by the Beijing Sci-Tech Medical Development Foundation and organized by GoBroad Healthcare Group, was successfully held on July 11–12.

This year's conference featured one main forum and six themed sub-forums, bringing together nearly 300 leading experts and scholars from China and abroad in fields such as hematopoietic stem cell transplantation, targeted and immunotherapy, lymphoma and myeloma, pediatric hematologic oncology, anemias and red blood cell disorders, diagnostic hematology, and hematologic nursing. Discussions centered around cutting-edge advances and future trends in the diagnosis and treatment of hematologic diseases, fostering strategy innovation, interdisciplinary consensus, and a shared vision for future development. The event became a vibrant convergence of frontier knowledge and clinical insight—shaping the future of hematology.

Opening Ceremony: Seven Years of Accumulation, a New Peak in the 8th Year

At the opening ceremony of the 8th GoBroad Medical Annual Meeting, guests reviewed the development journey of hematology in China and jointly envisioned its future. Speakers noted that in recent years, China's hematology discipline has made significant strides, with continuous innovation, a rapidly growing professional workforce, and a shift from "following" to "leading." GoBroad has played a pivotal role in developing a distinctive clinical system aligned with these transformations.

This conference was more than a platform for showcasing progress—it served as a catalyst for academic collaboration, innovation synergy, and high-quality development. Participants expressed a shared commitment to strengthening specialty capacity, accelerating research translation, contributing to the national "Healthy China" strategy, and actively engaging in global medical innovation.

 

Keynote Sessions: Driving the Frontier, Anchoring Innovation

A series of high-level academic presentations focused on core topics such as hematologic malignancies and hematopoietic stem cell transplantation, highlighting CAR-T therapy, post-transplant immune reconstitution, molecular pathology, and personalized treatment strategies.

Speakers provided systematic updates on CAR-T applications in leukemia, lymphoma, and CNS lymphoma, covering innovations in target optimization, dual-target constructs, bridge-to-transplant strategies, and toxicity management—demonstrating its transformative role in tackling high-risk, refractory diseases.

Sessions also delved into TCRαβ-depleted transplantation, allogeneic HSCT pathways for high-risk relapse patients, immune reconstitution rhythm, post-transplant relapse interventions, and real-world management of chronic viral infections. Additional reports covered immunosuppressive therapy in aplastic anemia, molecular subtyping in lymphoma, and industry-clinical collaboration, underscoring the momentum toward precision, standardization, and high-quality development in hematology.

 

Sub-Forums: Responding to the Era with Specialty Depth

Over the two-day event, six thematic sub-forums took place on July 11, delivering in-depth academic discussions across diverse hematology topics. Experts offered clinical perspectives, research insights, and forward-looking strategies, reflecting the multidisciplinary integration shaping the next phase of hematologic care in China.

 

l  Transplantation & Immunotherapy Forum

 

As a central pillar of hematologic treatment, hematopoietic stem cell transplantation and immunotherapy play a critical role in improving cure rates and survival. This forum highlighted the evolving synergy between transplant and immune-based therapies, exploring topics such as transplant pathway optimization, immune regulation mechanisms, and CAR-T advancements.

Discussions spanned infection control post-transplant, immune modulation across disease types, integrated management for refractory malignancies, and expanding CAR-T to non-hematologic tumors. Experts presented a multidimensional view of strategies for relapsed and refractory disease, positioning transplant-immunotherapy as a cornerstone of future precision care.

 

l  Lymphoma & Myeloma Immuno-Targeted Therapy Forum

The treatment paradigm for lymphoma has transitioned from conventional chemotherapy to precision-guided targeted therapy, leading to better outcomes and deeper discipline integration. The forum also marked the official launch of the Lymphoma Working Group under the Chinese Medical Women's Association Targeted Therapy Committee, establishing a new milestone for platform-based academic development.

Sessions explored CAR-T applications, first-line therapies for multiple myeloma driven by novel agents, and clinical strategies for rare lymphoma subtypes—highlighting the deep integration of molecular science and clinical translation.

 

l  Pediatric Hematologic Oncology Forum

Pediatric hematologic cancers are both a frontier and a challenge in medical research. In response to expanding disease spectrums and increasingly refined treatment demands, this forum gathered leading experts to explore key issues in pediatric leukemia, germline susceptibility genes in refractory lymphoma, primary immunodeficiency mutations, and transplant optimization for JMML. Case studies illustrated the translation of novel concepts into effective clinical models, offering robust strategies for personalized pediatric care.

 

l  Anemia & Red Cell Disorders Forum

As one of the most common and heterogeneous hematologic conditions, anemias and red cell disorders are deeply linked to systemic health and quality of life. With precision medicine advancing, this forum focused on mechanistic research, diagnosis refinement, and subtype management. Experts showcased clinical pathways from diagnosis to intervention, reflecting China's ongoing progress in enhancing red cell disease care.

 

l  Diagnostic Laboratory Forum

 Serving as the vital bridge between basic science and clinical care, diagnostic labs are pivotal in advancing precision hematology. This forum gathered experts in pathology, molecular biology, and cytogenetics to share breakthroughs in tumor mechanisms, immune escape, genetic analysis, and CAR-T expansion. The sessions underscored the essential role of diagnostics in disease identification and individualized treatment decision-making.

 

l  Nursing Forum

As hematology advances toward high-quality care, nursing remains a cornerstone of clinical management. The nursing forum emphasized the role of hematology nurses in treatment safety, complication management, psychosocial support, and care model innovation. Experts from top institutions engaged in discussions aligned with clinical needs, demonstrating nursing's strategic importance in enhancing treatment outcomes and patient experiences.

Closing Remarks: A Shared Future for Hematology

The 2025 GoBroad Hematology Academic Conference concluded successfully with brilliant insights and vibrant discussions. In her closing speech, Chairwoman Dr. Wu Tong expressed heartfelt gratitude to all participants both onsite and online.

She reflected on GoBroad's journey over the past seven years and its emergence as a premier platform for hematology exchange in China. The ideas and achievements shared at the forum continue to inspire clinical progress and drive quality development.

Looking ahead, the GoBroad hematology team remains committed to innovation, collaboration, and expanding access to affordable and effective cures for patients. With renewed confidence, insight, and inspiration from this conference, we eagerly await next year’s gathering—advancing hematology with broader vision, stronger partnerships, and greater ambition.